scholarly journals Discordant lymphoma consisting of splenic mantle cell lymphoma and marginal zone lymphoma involving the bone marrow and peripheral blood: a case report

2011 ◽  
Vol 5 (1) ◽  
Author(s):  
Giovanni Carulli ◽  
Alessandra Marini ◽  
Eugenio M. Ciancia ◽  
Joseph Bruno ◽  
Silvana Vignati ◽  
...  
Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 1800-1800
Author(s):  
Yin Xu ◽  
Prashanti Reddy ◽  
Xun Li ◽  
Riem Badr ◽  
Keming Lin ◽  
...  

Abstract Introduction : Mantle cell lymphoma is characterized by the t(11;14)(q13;q32) and can usually be recognized by its typical CD5+/CD23- immunophenotype. However, phenotypic variations have been observed and such variants can resemble other types of B-cell neoplasms, including chronic lymphocytic leukemia (CLL/SLL) and marginal zone lymphoma. In particular, the CD5- variant is diagnostically challenging. Some CD5- mantle cell lymphomas have been reported to have an indolent clinical course, while others follow an aggressive course similar to typical mantle cell lymphoma. To our knowledge, CD5- mantle cell leukemia has not been fully characterized. To further our understanding of this disease entity for diagnostic workup and risk assessment, we evaluated clinical, morphologic, immunophenotypic, and genetic features in a cohort of CD5- mantle cell leukemia. Methods: Among 111 cases of mantle cell leukemia identified from our database over a 2-year period, 12 were CD5- with t(11;14) and absolute peripheral lymphocytosis (>5,000/uL). Antigen expression was defined by flow cytometry as positive, dim positive, or negative. Conventional chromosome analysis and FISH were performed on all cases, including probes for 11q22.3 (ATM), 12 (CEP 12), 13q14, 13q34, 17p13 (TP53) and t(11;14) (IGH-CCND1). Other parameters obtained included age, gender, CBC, blood and bone marrow histology, and IgVH mutational status. Results: Of the 12 patients, 7 were female with a median age of 67 years (range: 55-88 years). Patients presented with marked lymphocytosis (mean: 55 K/uL) and mild normocytic anemia (mean: 11.3 g/dL). The average platelet count was within the low normal range (mean: 173 K/uL). Flow cytometric analysis showed that all cases expressed CD19 and surface light chain restriction (10 kappa and 2 lambda), and lacked CD5 and CD10. All except one case expressed CD20. CD23 was negative in 8 cases and dim positive in 4 cases. Thus, the leukemic phenotype was suggestive of a marginal zone lymphoma. Morphologically, the leukemic cells were small to medium sized with round nuclei and scant to moderately abundant cytoplasm. Bone marrow biopsy was performed in 6 of 12 cases. All 6 cases showed marrow involvement (mean: 45%; range: 25-85%) with interstitial and intrasinusoidal distribution patterns. While the marrow histology was suggestive of involvement by marginal zone lymphoma, immunohistochemical testing for cyclin D1 revealed positive nuclear staining in the leukemic cells. FISH for t(11;14) was positive in all 12 cases. In contrast, conventional chromosome analysis detected t(11;14) in only 6 cases (3 blood and 3 marrow samples). Additional cytogenetic abnormalities were detected in 8 (67%) patients. Five (42%) cases showed 17p deletion. Other abnormalities included 13q- (3/12; 25%), 11q- (2/12; 17%), and trisomy 12 (1/12; 8%). IgVH analysis was performed in 2 cases, and both exhibited IgVH hypermutation. Conclusions: CD5- mantle cell leukemia comprised approximately 11% of mantle cell leukemia in our series. In addition to t(11;14), other chromosome abnormalities were identified in the majority of the cases (67%). Deletion of 17p was most frequent, likely representing a more aggressive form in contrast to the previously described indolent form. The leukemic immunophenotype and marrow infiltration features resembled marginal zone lymphoma, indicating the importance of detecting t(11;14) for proper classification and clinical management of the disease. We observed that FISH was much more sensitive in detecting t(11;14) than conventional chromosome analysis. Therefore, performing FISH for t(11;14) and 17p- would be useful for diagnostic workup of mature B-cell leukemia regardless of CD5 positivity. Our limited observation of IgVH hypermutation in CD5- mantle cell leukemia would suggest future studies to investigate this potential relationship for prognostic implications. Disclosures No relevant conflicts of interest to declare.


2018 ◽  
Vol 3 (4) ◽  
Author(s):  
David Azoulay ◽  
Eugene Dementiev ◽  
Luba Trakhtenbrot ◽  
Netanel Horowitz ◽  
Tamar Tadmor ◽  
...  

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 1284-1284
Author(s):  
Christiane Pott ◽  
Sebastian Boettcher ◽  
Stefan Gesk ◽  
Reiner Siebert ◽  
Wolfram Klapper ◽  
...  

Abstract Two prospectively randomized intergroup trials of the European MCL Network investigating the impact of different combined immuno-chemotherapy protocols for patients with stage II–IV mantle cell lymphoma (MCL) >< 65 yrs followed by autologous stem cell transplantation (PBSCT) for patients <65 yrs and a rituximab or interferone maintenance treatment for patients >65 yrs are currently performed. Patients and methods: 180 German patients with diagnostic peripheral blood (PB) involvement detectable by consensus IGH PCR were analysed for t(11;14) translocation by FISH and 4-colour Flow Cytometry (FC) at diagnosis as well as molecular response (MR) by quantitative IGH-RQ-PCR after induction. The results were compared to clinical parameters at diagnosis and PFS. Results: Patients had a median age of 61 years, an elevated LDH in 37%, B-symptoms in 41% and extranodal involvement in 37%. According to the MIPI risk factor score 26% had an adverse, 34% an intermediate and 40% a good prognosis. PB involvement by MCL was demonstrated in 67% (74/111) by t(11;14) FISH and in 97% (152/156) by FC. Detection of MCL cells by FC in PB did not correlate with clinical parameters as stage, LDH, extranodal involvement or bone marrow infiltration. However, median % of MCL cells measured by FC differed significantly with clinical stage (p<0.0001), LDH (p=0.0096) bone marrow infiltration (<0.0001) and MIPI prognostic index (0.0002). MR after induction treatment was achieved in 60% (60/100) of patients and correlated with BM infiltration at diagnosis (p=0.0117). There was a trend for improved PFS in patients achieving MR (PFS 90% vs. 75% at 15 months after induction) however, the observation time is still too short for definitive evaluation. Conclusion: FC is highly sensitive for detection of PB involvement in MCL and improves staging accuracy. Achievement of MR might be an early indicator for treatment outcome after immuno-chemotherapy in MCL with the potential of defining prognostic subgroups.


2021 ◽  
Author(s):  
Rafael Bragança Rodrigues Matias ◽  
Bruna Cardoso de Mattos Boccalini ◽  
Renata de Oliveira Costa ◽  
Maria Fernanda Mélega Mingossi

Introduction: Mantle cell lymphoma (MCL) is a subtype of uncommon nonHodgkin lymphoma. The involvement of the central nervous system (CNS) is uncommon in the course of the disease. Objective: To report a case of recurrence of MCL in the CNS as the first manifestation, after chemotherapy and bone marrow transplantation. Case report: Male patient, 49 years old, with no previous comorbidities diagnosed with stage IV MCL (bone marrow), submitted to chemotherapy and autologous transplantation. After two years, he sought out the neurology clinic with a complaint of blurred vision. Neurological examination: without motor deficit; bilateral partial ptosis, bilateral divergent strabismus, tongue shift to the right. CSF with 230 leukocytes/mm³, 70% of lymphocytes, glucose of 71 mg /dl and protein of 85 mg /dl; Skull MRI demonstrated bilateral and symmetrical enhancement of segments of the cisterns of the optic and oculomotor nerves; Trigeminal, facial, vestibulocochlear and glossopharyngeal, vagus and accessory nerves more exuberant on the left. CSF immunophenotyping showed CD19, CD5 and Kappa positive monoclonal, compatible with MCL recurrence. Intrathecal and systemic chemotherapy with methotrexate were initiated. Discussion: Risk of recurrence of MCL and infiltration of the CNS is uncommon (3.9 - 5%). The patient did not show any signs of systemic involvement, only the neurological findings, which is atypical since the neurological presentation is more associated with recurrence of MCL with a course of systemic findings. Conclusion:The authors point out that in patients with treated MCL who have neurological manifestations without systemic findings, tumor recurrence should be considered.


Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 988-988
Author(s):  
Delphine Rolland ◽  
Ali Bouamrami ◽  
Benoit Ballester ◽  
Samuel Grangeaud ◽  
Marie Arlotto ◽  
...  

Abstract Non-germinal centre small B-cell lymphomas represent a heterogeneous group of non-hodgkin lymphomas which most frequent histologic subtypes are small lymphocytic lymphoma (SLL), marginal zone lymphoma (MZL) and mantle cell lymphoma (MCL). These three lymphoma entities have very different clinical outcomes but may be difficult to distinguish either histologically or clinically. We previously identified transcriptomic signatures specific of these 3 lymphoma subtypes. We further analyzed these lymphomas using Surface-Enhanced Laser Desorption/Ionisation Time of Flight (SELDI-TOF). A total of 58 tumors, including 20 SLL (all lymph nodes), 20 MZL (1 lymph node and 19 spleens) and 18 MCL (19 lymph nodes and 1 spleen) were analyzed. In addition, we included 7 controls obtained from traumatic normal spleens. The spectra were generated on weak cation exchange (CM10), strong anion exchange (Q10) and reversed-phase (H50) ProteinChip arrays. Protein patterns of all samples were comparatively analysed using two distinct strategies. We first used a binary recursive partitioning method with the Biomarker Pattern software (Ciphergen®), and second a hierarchical clustering method to visualized patterns of protein peaks completed with a supervised method (discriminating score) to point out individual peaks distinguishing the three histological subtypes (SLL, MZL and MCL). Spectra analyses revealed a very homogeneous protein patterns among all lymphoma samples. However specific SLL, MZL and MCL signatures based on 34 protein peaks with differential expression could be identified and allowed to classify 95% of the samples in their respective entity. SLL signature included 9 peaks, MZL signature 16 peaks and MCL signature 9 peaks. The binary recursive partitioning analysis was concordant but identified only the five most discriminant peaks. Further identification of the discriminating peaks is currently realized using SELDI-assisted purification. We are focusing on peaks at 9942 Da for SLL and at 11324 Da for MCL. Functional genomic studies can distinguish non-germinal small B-cell lymphomas at the transcriptomic level (our previous study) and at the proteomic level. This will provide new markers for diagnosis and potentially new therapeutic targets.


Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 4129-4129
Author(s):  
Kavita S. Reddy ◽  
Mohammad Ansari-Lari ◽  
Bruce Dipasquale

Abstract MYC rearrangements are not included as a genetic change in the blastoid variants of mantle cell lymphoma (Jaffe, et al (2001) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press.). We present two cases both with CCND1/IGH and MYC rearrangements. Case 1. An 82-year-old male with no known history of lymphoma presented with thrombocytopenia, loss of appetite and “abdominal fullness.” Imaging studies showed enlarged retroperitoneal lymph nodes. The peripheral blood smear had 18,000 WBC with approximately 30% circulating atypical lymphocytes. Flow cytometric studies of the bone marrow revealed a surface kappa light chain restricted CD10+ B-cell population. A bone marrow biopsy showed >90% of marrow cellularity comprised of neoplastic lymphocytes. The neoplastic lymphocytes were small to intermediate in size with minimal amounts of dark blue cytoplasm and several cytoplasmic vacuoles (Burkitt like morphology). By immunohistochemical stains, the neoplastic cells were positive for CD20, CD43, CD10, BCL-6, and cyclin D1, weakly and focally positive for BCL-2, and negative for CD23. The Ki-67 proliferation fraction was ∼100%. An immunohistochemical stain for CD5 was predominantly negative with a possible very faint blush on a subset of neoplastic B-cells. The FISH tests on bone marrow interphases were positive for a CCND1/IGH, a variant MYC/IGH, a variant MYC-BA rearrangements and negative for BCL6-BA and BCL2/IGH rearrangements. The variant MYC/IGH pattern was 3xMYC, 3xIGH, 1xFusion signals and MYC-BA pattern was 2x5′MYCcon3′MYC, 1x3′MYC. rearrangements. The karyotype was 44∼45,XY,del(2)(q11.2q21),der(3;17)(p10;q10), der(5)t(3;5)(q12;q15), t(11;14) (q13;q32) [cp6]/46,XY[14]. Since the karyotype had a t(11;14) and two normal 8 chromosomes, a metaphase FISH was analyzed to localize the signals for the MYC/IGH probe. The MYC signal were on both normal 8 chromosomes, a fusion signal was on a F-G sized chromosome. While the IGH signals were on the normal 14, der(14) and der(11). This was consistent with a cryptic MYC/IGH fusion in a three way rearrangement between chromosomes 8, 11 and 14. Case 2. A 69-year-old male having had a kidney transplant in 2001 was on immunosuppressive therapy. He presented with severe leukocytosis, anemia and thrombocytopenia and weight loss of about 12 pounds over several months. A peripheral blood smear showed 74,000 WBC with approximately 30% blasts. Bone marrow biopsies revealed normocellular bone marrow (50% cellularity). Interspersed large neoplastic lymphoid cells were shown by immunohistochemical stains to be positive for CD20, BCL-1, weak positive for BCL-2 and a Ki-67 staining > 90%. Flow cytometry indicated that the neoplastic cells were positive for kappa and CD5 but negative for CD11c and CD23. Interphases FISH on peripheral blood was positive for a CCND1/IGH rearrangement. The karyotype was 42∼44,X,-Y,add(1)(p13), t(2;8)(p12;q24), der(2)t(2;15)(p25;q11.2),+3,del(9)(p22p24),+del(9)(p22p24), − 10, del(11)(q21q23), t(11;14)(q13;q32) , − 13, − 15, − 17,add(17)(p11.2)[cp7]/46,XY[17]. FISH confirmed a MYC rearrangement. Therefore, this case had both CCND1/IGH and MYC/IGK rearrangement. Concomitant occurrence of a CCND1/IGH and a MYC rearrangement is rare in lymphomas. In Mitelman database of chromosome aberrations in cancer 2007, Four cases had both a t(11;14) and a t(8;14) translocation and two cases had both a t(11;14) and a t(2;8) translocation. This study expands the repertoire of abnormalities seen in blastoid transformation of mantle cell lymphoma. Being cognizant of a possible MYC involvement in the transformation of mantle cell lymphoma and its exploration would influence therapy.


Sign in / Sign up

Export Citation Format

Share Document